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Abstract 
Purpose: Plasma cell leukemia (PCL) is a rare form of plasma cell dyscrasia that presents either as 
a progression of previously diagnosed multiple myeloma, namely secondary PCL, or as initial 
manifestation of disease, namely primary PCL (pPCL). Although the presenting signs and 
symptoms include those seen in multiple myeloma, pPCL is characterized by several aspects that 
define a more aggressive course. Here, we have investigated the transcriptome of pPCLs and 
correlated differential expression profiles with outcome to provide insights into the biology of the 
disease.  
Experimental Design: The expression profiles of 21 newly diagnosed pPCLs included in a 
multicenter prospective clinical trial were generated using high-density microarray, then evaluated 
in comparison with a representative series of patients with multiple myeloma and in association 
with clinical outcome.  
Results: All but one of the pPCLs had one of the main immunoglobulin heavy-chain locus 
translocations, whose associated transcriptional signatures resembled those observed in multiple 
myeloma. A 503-gene signature distinguished pPCL from multiple myeloma, from which emerged 
26 genes whose expression trend was associated with progressive stages of plasma cells dyscrasia in 
a large dataset from multiple institutions, including samples from normal donors throughout PCL. 
Finally, 3 genes were identified as having expression levels that correlated with response to the 
first-line treatment with lenalidomide/dexamethasone, whereas a 27-gene signature was associated 
with overall survival independently of molecular alterations, hematologic parameters, and renal 
function.  
Conclusions: Overall, our data contribute to a fine dissection of pPCL and may provide novel 
insights into the molecular definition of patients with poorer prognosis. Clin Cancer Res; 19(12); 
3247–58. ©2013 AACR.  
Translational Relevance 
pPCL is a very aggressive and rare hematologic malignancy. So far, genomic and clinical 
differences between pPCL and multiple myeloma have been shown, mainly on the basis of 
retrospective studies. Here, we took advantage of a prospective series of pPCLs included in a phase 
II clinical trial to investigate pPCL global mRNA expression profiles. A 503-gene signature that 
distinguished pPCL from multiple myeloma was identified; a fraction of these genes have been 
suggested whose expression is putatively associated with the aggressiveness of clinical presentation. 
In addition, a 27-gene model has been identified with potential clinical relevance that distinguished, 
within pPCL, those with worst outcome. Because pPCL represents a high-risk clinical entity per se, 
our findings help provide insights into molecular features that could prognostically stratify patients 
with this aggressive form of plasma cell dyscrasia.  
 
Introduction 
Plasma cell leukemia (PCL) is a rare but highly aggressive disease that represents 3% to 5% of all 
plasma cell (PC) disorders. Its diagnosis is based on the Kyle criteria, which requires circulating 
PCs to account for at least 20% of peripheral blood leukocytes and/or an absolute circulating PC 
count of 2 × 10
9
/L, with evidence of monoclonal gammopathy. Clinically, the PCL can be 
distinguished into primary PCL (pPCL), originating de novo without any prior history of multiple 
myeloma, or secondary PCL (sPCL), arising from a preexisting multiple myeloma tumor that 
eventually progressed to the leukemic phase. The prognosis of pPCL is very poor and sPCL has the 
worst prognosis, with median survival durations of 7 to 11 months and 2 to 7 months, respectively. 
The pathogenetic mechanisms underlying either the de novo presentation or the aggressive 
transformation of relapse/refractory multiple myeloma are largely unknown (1).  
So far, few studies on both pPCL and sPCL have been conducted with an attempt to characterize the 
molecular alterations underlying PCL biology, mainly on the basis of immunophenotypic, 
fluorescence in situ hybridization (FISH) and cytogenetic or array-based comparative genomic 
hybridization (aCGH) analyses (2–6). All of them, albeit suffering restrictions of numerically 
limited cohorts of cases, agreed in identifying significant molecular differences among the multiple 
myeloma and PCL presentation, specifically in regard to the surface immunophenotype (the 
differential expression of CD20, CD56, CD9, CD117, and HLA-DR antigens) and the increased 
number of genomic aberrations identified in PCL (7). Indeed, PCL shows higher incidence of 
translocations involving immunoglobulin heavy-chain locus (IGH@) at 14q32, in particular 
t(11;14), whereas very few patients with hyperdiploidy have been reported differently from multiple 
myeloma (1). Among PCL, only t(4;14) was found to be associated with shorter overall survival 
(3), while controversial data exist on the favorable prognostic significance of t(11;14) [1]. MYC 
rearrangement, a late genetic event correlated with disease progression in multiple myeloma, has 
been frequently found in PCL also in association with a worse trend of the disease (5, 6).  
To date, high-resolution transcriptional profiling studies of PCL are limited to a retrospective small 
series reported by us (8) and the recently published investigation from Usmani and colleagues (9), 
who described pPCL cases included in the Total Therapy protocols database. Both studies indicated 
that transcriptional features may distinguish the 2 entities; moreover, in the latter study the authors 
additionally indicated that pPCL is an independent adverse prognostic factor in comparison with 
multiple myeloma.  
Here, we investigated a series of 21 previously untreated pPCL patients included in a prospective 
clinical trial using whole-transcript profiling arrays, and correlated the transcriptional profiles with 
the primary and secondary outcome endpoints to evaluate whether different molecular or clinical 
entities may exist within pPCL. In addition, we compared the transcriptional profiles of the 21 
pPCL with those of a representative dataset of 55 newly diagnosed primary multiple myeloma 
tumors; the differentially expressed genes were then evaluated in a large dataset, profiled on a 
different generation array platform, from multiple institutions including normal donors, different 
forms of PC dyscrasia from asymptomatic to aggressive stages, and a collection of human myeloma 
cell lines, with the aim to identify transcripts that might contribute to the pathogenesis of pPCL as 
well as to tumor progression in PC dyscrasia.  
 
Materials and Methods 
Patients 
Pathologic specimens were collected from 23 untreated pPCL patients included in a multicenter 
Italian clinical trial (RV-PCL-PI-350, EudraCT N° 2008-003246-28), an open-label, exploratory, 
single-arm, 2-stage study aimed at evaluating safety and antitumor activity of combined 
lenalidomide and dexamethasone (LD) as the first-line treatment of previously untreated pPCLs. All 
patients gave their informed consent for molecular analyses. The primary endpoint of the study was 
the response rate after a 4-cycle therapy over a 4-month schedule, according to International 
Uniform Criteria (10, 11); secondary endpoints were: (i) time to progression; (ii) progression-free 
and overall survival (OS); (iii) eligibility to undergo autologous or allogeneic stem cells 
transplantation after LD treatment; and (iv) serious/severe adverse event rate. Until February 2012, 
the median follow-up was 23 months (range, 9–32). To the purpose of the present work, we 
considered response rate and OS. Highly purified (≥90%) bone marrow PCs were obtained as 
previously reported (8). Demographic information and details on molecular alterations of the whole 
cohort were reported in a previous manuscript aimed at the genomic characterization of the samples 
(12). Fifty-five newly diagnosed multiple myeloma patients were included in the study; these cases 
have been previously reported (13) and were selected on the basis of the representativeness of the 
main molecular characteristics.  
Generation of gene expression data 
Total RNA was available from 21 pPCL and 55 multiple myeloma patients. Multiple myeloma 
samples were part of a larger cohorts previously profiled by us on old-generation array (GeneChip 
HG-U133A; ref. 13), herein resampled on newer generation arrays and selected on the basis of their 
representativeness of molecular features, to allow comparison with pPCL profiles. Preparation of 
DNA single-stranded sense target, hybridization to GeneChip Gene 1.0 ST arrays (Affymetrix Inc.), 
and scanning of the arrays (7G Scanner, Affymetrix Inc.) were carried out according to the 
manufacturer's instructions. Log2-transformed expression values were extracted from CEL files and 
normalized using NetAffx Transcript Cluster Annotations, Release 32 (June 2011) and Robust 
Multi-array Average (RMA) procedure in Expression Console software (Affymetrix Inc.). Non-
annotated transcript clusters were discarded. The expression values of transcript cluster ID specific 
for loci representing naturally occurring read-through transcriptions or mapped to more than 1 
chromosomal location were summarized as median value for each sample. The data have been 
deposited at NCBI Gene Expression Omnibus repository (http://www.ncbi.nlm.mih.gov/geo) and 
are accessible through GEO Series accession number GSE39925. The multiple myeloma samples 
were stratified into the 5 translocation/cyclin groups as previously described (14).  
The dataset of samples profiled on GeneChip HG-U133A arrays (Affymetrix Inc.) was generated by 
2 proprietary (GSE13591 and GSE6205) and 2 publicly available datasets (GSE6477 and 
GSE6691; refs. 15, 16), which globally included 24 healthy donors (N), 33 monoclonal 
gammopathy of undetermined significance (MGUS), 24 smoldering multiple myeloma (SMM), 200 
newly diagnosed and 26 relapsed multiple myeloma, 9 PCL patients (3 of whom primary), together 
with 23 HMCLs fully characterized in a previous study (17). Expression values were extracted from 
CEL intensity files using GeneAnnot custom chip definition files version 2.2.0 and normalized by 
Robust Multi-array Average procedure, as previously described (18). To prevent batch effects, 
namely the inclusion of low-quality or nonreproducible data, normalized unscaled standard error 
(NUSE) and relative log-expression (RLE) distributions were generated in aroma.affymetrix 
package for all samples; samples were removed if the 25
th
 or the 75
th
 percentile of NUSE and RLE 
exceeded the value of ±1.05 or ±0.5, respectively, which led to a definitive amount of 323 
comparable samples.  
Microarray data analysis 
Hierarchical agglomerative clustering was carried out on the list of genes whose average change in 
expression levels varied at least 2-fold from the mean across the considered data set, as previously 
reported (8). Euclidean and Ward were respectively used as distance and linkage methods in hclust 
function in R software.  
The differentially expressed genes discriminating the considered classes were identified using the 
Significant Analysis of Microarrays software version 4.00 as previously described (19). The 
functional annotation analysis on the selected lists was carried out using the gene set enrichment 
analysis (GSEA; ref. 20) to identify significantly enriched curated gene sets (version 3.0) among 
those included in the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/index.jsp). A 
false discovery rate that was lower than 25% was used as an enrichment statistic, and the rank was 
permuted with 1,000 permutations. Only gene sets including 5 through 1,000 genes were considered 
in the analysis.  
The Jonckheere–Terpstra test was used with the clinfun package in R software to investigate the 
significance of the trend from normal donors through PCL cases in the expression levels of the 
selected gene list generated on HG-U133A arrays. To avoid biases occurring conceivably due to 
variability in the target detection technology, the genes whose trend in multiple myeloma and PCL 
cases on HG-U133A arrays was incoherent with the data generated on HuGene1.0st arrays were not 
considered. For robustness, to reduce biases that might be due to numerical imbalances within the 
groups (with the multiple myeloma group being largely overrepresented) and to gain the most 
significant trends, an additional criterion was imposed that only steadily ascending or descending 
median values were allowed; in addition, a differential expression should be observed in at least 1 
condition (Kruskal–Wallis tests conducted using the stat package in R software). The Benjamini 
and Hochberg correction was used to adjust significance of multiple tests.  
Survival analysis 
A Cox proportional hazards model and 100.000 permutations were used in the globaltest function of 
R software to search for a correlation between the gene expression levels and OS (21). Patients 
were stratified into 2 groups using the prognostic gene signatures and hierarchical clustering with 
Euclidean and Ward as distance and linkage metrics, respectively. The groups identified by this 
approach were tested for association with survival using the Kaplan–Meier estimator and log-rank 
test, and P-values were calculated according to the standard normal asymptotic distribution. 
Survival analysis was conducted with the survcomp package in R software. Independence between 
commonly used prognostic factors and gene signatures was tested using multivariate Cox regression 
procedure of survival R package.  
Real-time quantitative polymerase chain reaction 
The expression levels of NFKBIA, RELB, RHOA, and SDC1 were analyzed in purified CD138+ 
cells by means of real-time quantitative PCR (qRT-PCR). Total RNA was converted to cDNA using 
M-MLV reverse transcriptase (Invitrogen). Inventoried or Made-to-Order TaqMan gene expression 
assays (Hs00153283_m1 for NFKBIA, Hs00232399_m1 for RELB, Hs01051295_m1 for RHOA, 
and Hs00896423_m1 for SDC1) and the TaqMan Fast Universal PCR Master Mix were used 
according to the manufacturer's instructions (Applied Biosystems). GAPDH-specific predeveloped 
assay reagent (PDAR, Applied Biosystems) was used as the internal control. The measurement of 
gene expression was done using the ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems). All the samples were run in duplicate. Data were expressed as 2
−ΔCt
 (Applied User 
Bulletin No. 2).  
 
Results 
Association between primary IGH translocation and the transcriptional profiles 
of pPCL tumors  
Here, we analyzed the transcriptional profile of 21 of the 23 pPCLs (for whom RNA material was 
available) included in the prospective Italian multicentric clinical trial RV-PCL-PI-350, all of which 
were characterized by FISH for the main genomic aberrations. Specifically, 3 of them had t(4;14), 9 
had t(11;14), 7 had t(14;16), and 1 had t(14;20); notably, only 1 patient lacked any of these major 
IGH translocations (12). In addition, we generated the gene expression profiles of 55 primary 
multiple myeloma tumors, representative of the type and frequency of the major molecular 
aberrations of this clinical entity. Unsupervised analysis was carried out on the 1,145 most variable 
transcripts in the 21 pPCLs dataset to evaluate whether natural grouping of the transcriptional 
profiles might be associated with distinct molecular subgroups. Indeed, as shown in Fig. 1A, the 
hierarchical clustering was mostly driven by the presence of the main recurrent IGH chromosomal 
translocations. Specifically, all cases with translocated MAF genes clustered in 1 main branch (P = 
4.423e-05), whereas the t(11;14)- and t(4;14)-positive pPCLs were clustered together in the second 
branch. Within the MAF-translocated PCL, a sample was clustered lacking major translocations 
(PCL-020), with expression profile resembling those of MAF/MAFB samples, in all likelihood due 
to the exclusive and spiked expression of MAFA, another member of the MAF family transcription 
factor (Supplementary Fig. S1). Unfortunately, lack of available material did not allow investigation 
of the occurrence of a translocation event.  
 
 
Figure 1. A, hierarchical clustering analysis of gene expression profiles of 21 pPCL cases. Samples are 
grouped according to the expression levels of the 1,145 most variable genes. Main molecular alterations 
are shown; black indicates occurrence. B, heatmap of the 47 differentially expressed genes identified by 
multi-class analysis of 21 pPCL patients stratified into the 3 main IGH translocation groups. Visualization of 
the expression in multiple myeloma samples is included. In the heatmap, the color-scale bar represents the 
relative gene expression changes normalized by the SD, and the color changes in each row represent gene 
expression relative to the mean across the samples.  
We conducted a multi-class supervised analysis to identify genes that might specifically 
differentiate pPCL cases stratified on the main IGH chromosomal translocations. Forty-seven genes 
were differentially expressed in the 3 classes (Fig. 1B; Supplementary Table S1). As expected, the 
direct targets of t(11;14) (CCND1), t(4;14) (WHSC1), and MAF genes were found to be 
respectively upregulated in each corresponding pPCL subgroup (to the aim of the analysis, PCL-
020 was considered part of the MAF group). The FGFR3 gene was not identified in the gene 
signature of the t(4;14), likely due to a missing derivative chromosome 14 in 1 of the 3 cases. 
Notably, the CCND2 transcript showed the highest score and positively marked both the MAF 
cases and, although at a lesser extent, the t(4;14)-translocated pPCLs. As depicted in Fig. 1B, the 
signatures of the IGH translocations largely resembled those observed in multiple myeloma and, in 
part, previously described.  
Identification of a 503-gene transcriptional signature distinguishing pPCL from 
multiple myeloma 
On the basis of its clinical presentation, it is conceivable that pPCL is characterized by distinct 
transcriptional patterns from intramedullary multiple myeloma. We, therefore, investigated the 
relationship between the transcriptional profiles of pPCL and multiple myeloma tumors. First, we 
carried out hierarchical clustering of the 1,166 most variable genes in the dataset, including the 21 
pPCL and 55 multiple myeloma cases (Fig. 2). Again, the clustering was mainly driven by the IGH 
translocations: in fact, t(14;16)/t(14;20) or t(4;14) or t(11;14) cases clustered together independent 
of belonging to multiple myeloma or pPCL groups, suggesting that such translocation events had 
stronger consequences on the transcriptional fingerprint than those due to leukemic phenotype.  
 
Figure 2. Hierarchical clustering analysis of gene expression profiles of 21 pPCL and 55 multiple myeloma 
cases. Samples are grouped according to the expression levels of the 1,166 most variable genes. Main 
molecular alterations are indicated as black boxes, as well as the pPCL type in the last lane.  
Next, in order to identify the genes that specifically distinguished the 2 clinical entities, we 
conducted a supervised analysis between the 21 pPCL and the 55 multiple myeloma cases. We 
found 503 differentially expressed genes, 366 of which upregulated in pPCLs (Supplementary 
Table S2). Functional annotation analysis was conducted using GSEA (Supplementary Table S3). 
Among the identified gene sets, it is worth mentioning those associated with the NF-kB pathway, 
structural organization of the cell, and migration, together with some gene sets that suggested 
putative alterations of CD40, TGFB, AKT, and FAS signaling pathways. Notably, the SDC1 gene, 
codifying the CD138 surface antigen, showed significantly lower expression level in pPCLs. 
Prompted by these findings, on the basis of gene expression data, we evaluated whether pPCL cases 
were likely to show more activated NF-kB pathway or higher proliferation pattern. To this aim, we 
took advantage of the NF-kB indexes on the basis of expression data as described by Annunziata 
and colleagues (22) and Keats and colleagues (23); and the proliferation indexes as described by 
Hose and colleagues (24), Bergsagel and colleagues (25), and Zhan and colleagues (26). 
Interestingly, both the procedures for NF-kB indexes calculation highlighted increased NF-kB 
pathway activity in pPCL (Supplementary Fig. S2A and 2B); conversely, no significant difference 
was raised according to the gene proliferation indexes (Supplementary Fig. S2C–2E). As a 
methodologic validation of our results, 4 of the genes identified and included in the mentioned gene 
sets (NFKBIA, RELB, RHOA, and SDC1) were validated by qRT-PCR in all samples for which 
RNA was available (15 pPCL and 40 multiple myeloma patients; Supplementary Fig. S3). The 
correlation coefficients of the expression of each gene as determined by microarray or qRT-PCR 
indicated an optimal concordance for all genes (median Pearson correlation coefficient, 0.73).  
Modulation of genes included in multiple myeloma-pPCL signature throughout 
the different stages of PC dyscrasia 
We hypothesized that the identified 503-gene signature distinguishing pPCL and multiple myeloma 
cases could be accountable to the occurrence of overt/aggressive disease. Therefore, we tried to 
elucidate whether the genes of this list, or at least a part of them, may be modulated through (if not 
discriminate) the different stages of the disease; namely, whether the expression trend of these 
transcripts could underlie the transition from indolent forms to aggressive stages. To verify this, we 
generated a comprehensive dataset including independent samples from 3 different cohorts, 
encompassing PC samples from normal subjects, MGUS, smoldering multiple myeloma, newly 
diagnosed multiple myeloma, and PCL patients, all profiled on the HG-U133A microarray chip. Of 
the public available samples, 274 passed the quality controls applied to prevent biases due to inter-
cohort analysis. In this dataset, we investigated the expression profiles of 360 of the 503 
differentially expressed transcripts represented on the HG-U133A array, and tested whether a trend 
existed in their expression levels through all the progressively malignant stages of PC dyscrasia. We 
selected the 26 most significant genes (Supplementary Fig. S4A) whose trend in expression levels 
correlated with progressive disease. Larger expression level spreads were observed in multiple 
myeloma subgroups than in other stages, in line with the well-accepted notion that multiple 
myeloma represents a widely heterogeneous entity. However, no significant associations were 
found between the expression levels of the 26 genes and the molecular stratification of the myeloma 
samples on the basis of the occurrence of IGH translocations, with few marginally significant 
exceptions (Supplementary Fig. S4B). In addition, we evaluated the expression profiles of those 360 
genes in 26 relapsed multiple myeloma and 23 HMCLs. Notably, although not included in the 
analysis, the trend of the expression values of all the genes in HMCLs was concordant with that 
observed in primary tumors, thus reinforcing the suggestion that the deregulation of these genes 
(either with increasing or decreasing pattern) is compatible with the “strength” of neoplastic 
transformation. Among the identified transcripts, it is worth mentioning the proteasome-associated 
gene PSMD6 and the polycomb group protein codifying gene EZH2, whose expression has been 
associated with tumor burden in multiple myeloma (27).  
Identification of transcriptional profiles with clinical relevance in the definition 
of pPCL with poorer outcome 
Finally, the transcriptional features of pPCL were evaluated in the context of the outcome data of 
the prospective series of pPCL patients. In particular, we evaluated whether the occurrence of 
specific gene signature might be associated either with response rate or OS. To this aim, we first 
investigated the dataset for differentially expressed genes in patients who failed to respond to 
frontline 4-cycle therapy of LD. The analysis led to the identification of 3 genes (YIPF6, EDEM3, 
and CYB5D2) able to distinguish nonresponder patients from responders [i.e., complete response 
(CR), very good partial response (VGPR), and partial response (PR); Fig. 3]. When PR, VGPR, and 
CR were considered separately, no specific differentially expressed genes could be evidenced. The 
identified transcriptional pattern will be helpful to integrate results on efficacy and side effects of 
the first-line treatment of LD in pPCL.  
 Figure 3. Boxplot distribution of the expression levels of the 3 differentially expressed genes identified by 
supervised analysis of pPCL patients stratified according to response rate. NR, nonresponder; PR, partial 
remission; VGPR, very good partial remission; CR, complete remission.  
Next, we assessed the relationship between each of the 1145 most variable genes across the pPCL 
dataset and OS, using a statistical approach based on the linear regression model in which the 
distribution of the response variable is modeled as a function of the expression levels of each gene. 
Of the 1145 genes, 27 reached a highly significant correlation (P < 0.01) with OS (Table 1). On the 
basis of this 27-gene model, the 18 pPCL cases for whom follow-up information was available 
could be divided into 2 groups, of 6 and 12 patients respectively, who showed different outcomes 
(Fig. 4A and B). This model retained independency from all the molecular characteristics available 
(Table 2), as well as from age, sex, lactate dehydrogenase (LDH) levels, renal function, and 
hematologic parameters (data not shown). However, it is worth mentioning that none of the 
cytogenetic aberration was associated per se with OS (12). It is also worth emphasizing that the 27-
gene model was not independent of patients being subjected to autologous stem cell transplantation 
(ASCT), indicating that this therapeutic approach points definitively toward a more favorable 
outcome.  
 
Figure 4. A, heatmap of the pPCL samples clustered on the 27 genes identified by globaltest as significantly 
associated with OS. Molecular features are indicated above the heatmap (black indicates occurrence). B, 
Kaplan–Meier curves of the 2 groups defined by the 27-gene model. The colors of the groups correspond to 
those shown in the dendrogram in A.  
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Table 1.  List of the 27 genes with P < 0.01 in globaltest analysis of expression data and OS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Multivariate analysis comparing the 27-gene model with molecular variables and UAMS, IFM, and 
UK gene-risk models in pPCL series  
 
 
We finally tested the independency of the 27-gene model from other gene-risk models on the basis 
of gene expression data described in multiple myeloma (28–30). Specifically, to this aim, we first 
stratified the samples included in our dataset according to the criteria defined by the UAMS 70- and 
17-gene models from Shaughnessy and colleagues (30), the IFM 15-gene model by Decaux and 
colleagues (28), and the UK 6-gene model by Dickens and colleagues (29). Of them, only UAMS 
models effectively stratified pPCL patients into 2 significantly different risk groups (data not 
shown). Importantly, the 27-gene model retained significant correlation with outcome against both 
UAMS and other models (Table 2).  
 
Discussion 
In the present study, we reported a comprehensive molecular and transcriptional analysis of a series 
of pPCLs patients included in a prospective clinical trial aimed at exploring efficacy and safety of 
the LD combination as first-line therapy in previously untreated patients. The analysis was 
particularly aimed at identifying those transcriptional features that may contribute to explain the 
aggressive phenotype of PCL, as well as at correlating their gene expression profiles with the 
clinical outcome.  
According to previous reports (2, 4–6), a high incidence of the 14q32 translocations was found in 
our series of pPCLs. The transcriptional analysis further supported that the main IGH chromosomal 
translocations drive pPCL patients clustering and are associated with specific signatures, as it 
occurs in multiple myeloma. The combined analysis of pPCL and multiple myeloma patients 
confirmed that pPCLs and multiple myelomas clustered together in specific IGH translocation 
groups, thus suggesting that the transcriptional effects related to these translocations have an impact 
that overcomes the signatures related to the specific disease. Moreover, the supervised analysis 
revealed that IGH translocations have transcriptional effects in pPCL cases that actually resembled, 
in a virtually identical fashion, those observed in multiple myeloma, identifying transcripts that 
have been shown as direct or indirect targets of the translocations in multiple myeloma, as 
previously described (14). Conversely, no association has been found in our dataset between 
cytogenetic abnormalities and clinical outcome. Therefore, occurrence of IGH translocations in a 
very large fraction, if not almost the totality, of pPCL cases was not conceivable to justify per se the 
more aggressive phenotype of leukemic forms than the large majority of multiple myeloma.  
We thus aimed our analysis at investigating the transcriptional pathways differentially expressed in 
pPCL with regard to multiple myeloma condition. Of the 503-gene signature identified, several 
genes have been identified as related to cytoskeleton functions and Rho protein signaling pathway 
(31–33), involved in cell adhesion/migration processes. Our analysis also highlighted the 
involvement of NF-kB pathway-associated genes, specifically acting as functional regulators in NF-
kB pathway or potentially responsive to NF-kB transcriptional modulation. In particular, the RelB 
subunit involved in NF-kB noncanonical pathway, whose activation was found to be associated to 
the cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (34), was upregulated 
in pPCLs as well as the inhibitory subunits NFKBIE (IkBε) and NFKBIA (IkBα). In addition, 
TRAF1, TRAF4, and TRAF5, members of the family of TNF–receptor-associated factor with 
different roles in NF-kB pathway, were expressed at higher level in pPCLs (35, 36). Overall, these 
considerations, together with the concurrent findings of higher NF-kB indexes in pPCL cases, are 
suggestive and compatible with more activated NF-kB pathway and aggressive phenotype in pPCL. 
Conversely, a limited, if not absent, discrepancy between pPCL and multiple myeloma has been 
identified, according to published expression-based indexes (24–26), as regards proliferation. This 
might be explained in that such indexes were mainly derived by the comparison between primary 
tumors and cell lines that might, therefore, account for more enhanced proliferation activity in 
relapsed/refractory myeloma, evolving to a more aggressive and uncontrolled leukemic progression. 
The transcriptional pattern of pPCL was recently investigated by Usmani and colleagues, who 
characterized the clinicobiological features of a series of pPCL patients, partly included in the Total 
Therapy protocols trials (9), suggesting that pPCL represents a highly significant adverse feature of 
myeloma tumors in relationship with both OS and PFS as well as CR duration. This was further 
supported by the occurrence of high-risk variables (advanced age; abnormal albumin, LDH, and β2-
microglobulin levels; chromosome abnormalities, etc.) that undoubtedly confer to pPCL a highly 
aggressive phenotype with very poor outcome. They described a 203-gene signature, obtained from 
20 pPCL cases, that only in a minimal part (∼15%) overlapped with our 503-gene list. As possible 
explanations to this finding, the new-generation arrays used in our analysis (leading to only 125 
transcripts commonly represented on the 2 platforms) and the different balance between pPCL and 
non-pPCL samples in the 2 datasets could be considered. Moreover, the authors did not provide 
specific information on the molecular alterations (translocations, deletions, and amplifications) of 
their cases; therefore, we could not exclude that different stratification within pPCL cases might 
affect the differential expression analysis. Furthermore, their data were not available in public 
repositories, which prevented any meta-analyses, validation, or verification of similarities and 
differences between the 2 datasets.  
On the basis of the list of differentially expressed genes between pPCL and multiple myeloma, we 
took advantage of a composite dataset from multiple institutions to investigate whether the 
modulation of expression levels of some transcripts included in the 503-gene signature might be 
correlated with progression in PC dyscrasias, provided that the increased or decreased expression 
could be due to or associated with features characterizing highly injured PCs and/or aggressive 
clinical course. Among the 26 genes with a significant trend (8 decreasing and 18 increasing) from 
normal PC condition to PCL through the different forms of PC dyscrasia, it is worth mentioning the 
methyltransferase EZH2, whose expression correlates with tumor burden during multiple myeloma 
disease progression and which is constitutive in IL–6-independent cell lines (27), and that was 
among the most overexpressed genes associated with the proliferation (PR) multiple myeloma 
subgroup in the UAMS classification (26). Overall, the 26 genes identified here showed significant 
modulation in the expression levels through the different progressive presentation of PC dyscrasia 
and exhibited further enhanced expression levels in HMCLs in line with the trend in primary 
tumors, thus strengthening the putative involvement of these genes in sustaining the 
intensity/aggressiveness of the neoplastic phenotype.  
A further finding of the present study was the identification of distinct transcriptional signatures in 
groups of pPCL that clearly showed different outcome. The 27 genes carrying a highly significant 
correlation with OS were prevalently upregulated (17/27, 63%) in the pPCL patients with the 
poorest outcome. The occurrence of this peculiar pattern is predictive of poorer OS, independent of 
the major cytogenetic alterations, hematologic parameters, and known multiple myeloma gene-risk 
models. Conversely, the low-risk signature is strongly associated with the ASCT procedure, which 
points to a more favorable prognosis overall. Further investigations on larger cohorts and validation 
sets are warranted to better elucidate whether a specific transcription pattern at diagnosis may be 
suggestive of the eligibility of the patients to ASCT with consequently associated better outcome. 
Interestingly, none of the 27 genes were recognized in known multiple myeloma high-risk 
signatures (24, 28, 30), whereas only a minor fraction were dispersedly included in the gene lists 
characterizing the 7 multiple myeloma molecular subgroups in the UAMS database (26). 
Interestingly, the platelet/endothelial cell adhesion molecule 1 (PECAM1), whose expression was 
most significantly associated with OS, encoded a member of the immunoglobulin superfamily 
involved in angiogenesis and activation of integrins. Notably, a recent work described its 
involvement in the lenalidomide effect in angiogenesis inhibition and the interaction with cadherin 
5 and β-catenin, which is critical for endothelial cell cord formation (37). It could be speculated that 
the lower levels of PECAM1 associated with more aggressive disease might lead to less 
dependency of malignant PCs from microenvironment and reduced substrates for drugs, such as 
lenalidomide, that target microvessel formation.  
The primary endpoint of the study was set to response after 4 cycle of therapy; 6 patients failed to 
reach response; the gene expression analysis highlighted 3 genes that clearly distinguished 
nonresponders from responders (albeit at different treatment response, from partial to complete) to 
the treatment with LD. Little is known about the biological role and the function of CYB5D2, 
EDEM3, and YIPF6, which leaves open the investigation of these genes as putatively involved in 
drug response or associated with PCs with a resistant phenotype. Additional studies on larger 
cohorts are warranted on this aspect.  
Overall, our data suggest that pPCL might not represent a unique transcriptional and clinical entity, 
albeit clearly distinguishable from multiple myeloma on the basis of the expression of a large 
signature, and provide insights for further investigations of mechanisms underlying the biology of 
aggressive forms of PC dyscrasia.  
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